Photo: Teerapat Seedafong/EyeEm/Getty
More than 75 percent of ovarian cancer cases remain undiagnosed until the disease has reached an advanced stage.
A recent clinical trial conducted at nearly 200 sites around the world, including 好色tv Langone鈥檚 Perlmutter Cancer Center, showed that niraparib, a type of drug known as a poly ADP ribose polymerase (PARP) inhibitor, reduced disease progression 57 percent, and the time to disease progression was prolonged 12 months. Bhavana Pothuri, MD, professor in the and a co-investigator of the study, discusses the results on WCBS Newsradio 880.
鈥淭he study results move PARP inhibitors for all patients into the front line after platinum-based chemotherapy and really should be considered a new standard of care,鈥 Dr. Pothuri says.
Listen to Dr. Pothuri鈥檚 full interview on .
